Jeff Yass’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $706K | Sell |
1,899
-7,143
| -79% | -$2.13M | ﹤0.01% | 9082 |
|
|
2026
Q1 | $2.34M | Buy |
9,042
+7,175
| +384% | +$1.91M | ﹤0.01% | 5811 |
|
|
2025
Q4 | $460K | Buy |
+1,867
| New | +$393K | ﹤0.01% | 8984 |
|
|
2025
Q3 | – | Sell |
-30,252
| Closed | -$4.53M | – | 13211 |
|
|
2025
Q2 | $4.16M | Sell |
30,252
-3,577
| -11% | -$525K | ﹤0.01% | 4323 |
|
|
2025
Q1 | $6.1M | Sell |
33,829
-4,639
| -12% | -$780K | ﹤0.01% | 3285 |
|
|
2024
Q4 | $6.03M | Buy |
38,468
+28,914
| +303% | +$5.13M | ﹤0.01% | 3326 |
|
|
2024
Q3 | $1.74M | Buy |
9,554
+4,070
| +74% | +$785K | ﹤0.01% | 5562 |
|
|
2024
Q2 | $1.01M | Sell |
5,484
-96,073
| -95% | -$16.1M | ﹤0.01% | 6578 |
|
|
2024
Q1 | $18.1M | Buy |
101,557
+93,515
| +1,163% | +$13M | ﹤0.01% | 1895 |
|
|
2023
Q4 | $998K | Buy |
8,042
+898
| +13% | +$99.6K | ﹤0.01% | 7002 |
|
|
2023
Q3 | $829K | Buy |
7,144
+762
| +12% | +$93K | ﹤0.01% | 7070 |
|
|
2023
Q2 | $749K | Sell |
6,382
-19,737
| -76% | -$2.02M | ﹤0.01% | 7355 |
|
|
2023
Q1 | $2.09M | Buy |
26,119
+17,927
| +219% | +$1.41M | ﹤0.01% | 5034 |
|
|
2022
Q4 | $649K | Sell |
8,192
-12,058
| -60% | -$895K | ﹤0.01% | 7201 |
|
|
2022
Q3 | $1.41M | Buy |
20,250
+3,999
| +25% | +$289K | ﹤0.01% | 5739 |
|
|
2022
Q2 | $1.07M | Buy |
16,251
+1,138
| +8% | +$70.8K | ﹤0.01% | 6368 |
|
|
2022
Q1 | $1.01M | Buy |
15,113
+1,629
| +12% | +$102K | ﹤0.01% | 7102 |
|
|
2021
Q4 | $943K | Buy |
13,484
+1,028
| +8% | +$59.8K | ﹤0.01% | 7465 |
|
|
2021
Q3 | $650K | Buy |
12,456
+4,855
| +64% | +$287K | ﹤0.01% | 8710 |
|
|
2021
Q2 | $517K | Sell |
7,601
-2,876
| -27% | -$201K | ﹤0.01% | 9500 |
|
|
2021
Q1 | $807K | Sell |
10,477
-11,726
| -53% | -$853K | ﹤0.01% | 8282 |
|
|
2020
Q4 | $1.33M | Buy |
22,203
+9,925
| +81% | +$496K | ﹤0.01% | 6018 |
|
|
2020
Q3 | $529K | Sell |
12,278
-5,554
| -31% | -$241K | ﹤0.01% | 7546 |
|
|
2020
Q2 | $739K | Buy |
17,832
+11,293
| +173% | +$543K | ﹤0.01% | 6551 |
|
|
2020
Q1 | $283K | Buy |
+6,539
| New | +$342K | ﹤0.01% | 8090 |
|
|
2019
Q4 | – | Sell |
-6,630
| Closed | -$230K | – | 10203 |
|
|
2019
Q3 | $230K | Buy |
6,630
+416
| +7% | +$18.6K | ﹤0.01% | 8831 |
|
|
2019
Q2 | $250K | Sell |
6,214
-39,279
| -86% | -$1.28M | ﹤0.01% | 8673 |
|
|
2019
Q1 | $1.5M | Buy |
45,493
+26,796
| +143% | +$632K | ﹤0.01% | 4244 |
|
|
2018
Q4 | $389K | Buy |
+18,697
| New | +$391K | ﹤0.01% | 6516 |
|
Other funds holding KRYS
ACA
SCM
Jeff Yass's KRYS Position: Q2 2026 in Review
Jeff Yass reduced its Krystal Biotech (KRYS) stake by 79% in Q2 2026, selling an estimated $2.13M and leaving 1,899 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #9082.
Jeff Yass first reported a position in KRYS in Q4 2018 and has held it in 29 quarters since. The position peaked at $18.1M in Q1 2024. 421 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- Jeff Yass held 1,899 shares of Krystal Biotech worth $706K as of Q2 2026.
- Jeff Yass sold 7,143 Krystal Biotech shares in Q2 2026, an estimated $2.13M.
- Krystal Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9082 holding.
- Jeff Yass first reported a position in Krystal Biotech in Q4 2018 and has held it in 29 quarters since.
- Jeff Yass's Krystal Biotech position peaked at $18.1M in Q1 2024.
- 421 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.